{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 112 of 122', 'Appendix 4: Study Schedule of Activities for AR101 Treatment: Initial Dose Escalation and Up-Dosing', 'Study Period', 'Initial Dose Escalation', 'Up-Dosing', 'Early', 'Study Visit', 'Day 1 [1]', 'Day 2 [2]', 'At Study Site', 'At 80 mg', 'At 300 mg', 'Unsched [3]', 'Disc [4]', 'Interval', 'na', 'na', 'Every 2 weeks', 'Varies', 'Varies', 'Varies', 'Varies', 'Window (Days)', 'na', 'na', '3', '+3', '+3', 'na', '+3', 'HRQOL Questionnaires and Bespoke Questions [5]', 'EQ-5D [6]', 'X', 'X', 'X', 'x[7]', 'FAQL-PB [8]', 'X', 'X', 'HADS [8]', 'X', 'X', 'FAQLQ, FAIM [9]', 'X', 'X', 'X', 'x[7]', 'Bespoke global assessment of HRQOL', 'X', 'X', 'Bespoke assessment of control and confidence', 'X', 'X', 'Randomization', 'X', 'General Activities', 'Weight, height', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Vital signs (blood pressure, heart rate, temperature)', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'ACT/C-ACT, SCORAD, TNSS (if completed at screening)', 'X', 'X', 'X (optional)', 'X', 'PEFR [10]', 'X', 'X', 'X', 'X', 'X', 'X (optional)', 'X', 'Asthma evaluation [11]', 'X', 'X', 'X (optional)', 'X', 'Symptom-directed physical examination [12]', 'X', 'X', 'X', 'Complete physical examination [12]', 'X', 'X', 'X', 'X (optional)', 'X', 'Diet/food allergen exposure review', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Food allergy instruction [13]', 'X', 'X', 'X', 'X', 'X', 'X (optional)', 'X', 'Contraception review', 'X', 'X', 'X', 'X', 'X', 'X (optional)', 'Adverse events review [14]', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Concomitant medications review & instruction [15]', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Study product administration [16]', 'X', 'X', 'X', 'X', 'X', 'X (optional)', 'Study product dispensing [17]', 'X', 'X', 'X', 'X', 'X (optional)', 'Study product accountability', 'X', 'X', 'X', 'X (optional)', 'X', 'Telephone call [18]', 'X', 'X', 'X', 'X', 'X (optional)']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 113 of 122', 'Study Period', 'Initial Dose Escalation', 'Up-Dosing', 'Early', 'Study Visit', 'Day 1 [1]', 'Day 2 [2]', 'At Study Site', 'At 80 mg', 'At 300 mg', 'Unsched [3]', 'Disc [4]', 'Interval', 'na', 'na', 'Every 2 weeks', 'Varies', 'Varies', 'Varies', 'Varies', 'Window (Days)', 'na', 'na', '3', '3', '3', 'na', '3', 'Laboratory Evaluations [19]', 'Urine pregnancy test [20]', 'X', 'X', 'X (optional)', 'X', 'Blood sample for basophil activation test (BAT)', 'X', '[1]', 'Day 1 HRQOL questionnaires and bespoke questions are to be administered after eligibility is confirmed and must be completed before randomization.', 'Day 1 activities must begin within 28 days after obtaining signed consent/assent and should be the same day as randomization', '(within', '3', 'days', 'after', 'randomization only if the same day is not feasible). The timing of day 1 study product administration, vital signs, and assessment of allergic reactions', 'for initial dose escalation is presented in Table 3.', '[2]', 'Day 2 should be the next consecutive day after day 1. If circumstances (eg, an intercurrent illness) create a safety risk, day 2 may be delayed up to', '7 days after day 1.', '[3]', \"Anytime necessary to assess or follow up adverse events, at the subject's request, or per investigator decision. Perform procedures, spirometry, and\", 'laboratory tests as appropriate.', '[4]', 'For subject unable to complete initial dose escalation or up-dosing; approximately 14 days after the last dose.', '[5]', 'Instruct subject and parent/caregiver to complete HRQOL questionnaires and bespoke questions at the start of the visit before other procedures (unless', 'specified otherwise). The same parent/caregiver should complete all relevant questionnaires during the study.', 'For age-relevant questionnaires, subject who transitions from one age group to the next age group during the study will complete the version first used.', '[6]', 'Parent/caregiver: EQ-5D-5L, EQ-5D-Y proxy (for subject aged 4-7 years); subject aged 8-12 years: EQ-5D-Y; subject aged 13-17 years: EQ-5D-5L.', 'In addition, instruct subject and parent/caregiver to complete the questionnaire as follows:', 'Before leaving the study site if severe dose-related allergy symptoms occur during an up-dosing visit (Section 8.5.1), and 1 week', 'later.', 'When allergy symptoms due to study product or food allergen exposure are reported to the study site and assessed as severe (Section 8.5.6.3), and', '1 week later.', '[7]', 'Subject discontinuing before the start of maintenance: Subject and parent/caregiver will complete relevant EQ-5D, FAQLQ, and FAIM questionnaires', 'at early discontinuation and 12 and 18 months after day 1.', '[8]', 'For parent/caregiver.', '[9] Parent/caregiver of subject aged 12 years: FAQLQ-PF and FAIM-PF; parent/caregiver of subject aged 13-17 years: FAQLQ-PFT and', 'FAIM-PFT;', 'subject aged 8-12 years: FAQLQ-CF and FAIM-CF; subject aged 13-17 years: FAQLQ-TF and FAIM-TF.', '[10]', 'For subject aged > 6 years, obtain PEFR at approximately the same time of day for each assessment visit (eg, morning, afternoon); record the best', 'result of 3 attempts. Obtain spirometry (FEV1) if PEFR shows a clinically relevant reduction, subject has clinical deterioration (eg, active wheeze on', 'physical examination), or as clinically indicated at unscheduled visits; record the best result of 3 attempts (if unable to successfully obtain, record', 'attempts and investigator assessment).', 'For subject aged 4-5 years, obtain PEFR; record results (if unable to successfully obtain, record attempts and investigator assessment).']\n\n###\n\n", "completion": "END"}